Evidece that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis [1]

Bipolar Disorders

Volumn 7, Issue 4, 2005, Pages 388-389

  Kniff, Esther M ^a   Kupka, Ralph W ^b   Ruwhof, Cindy ^a   Breunis, M Nadine ^a   Prens, Errol P ^a,c   Nolen, Willem A ^d   Drexhage, Hemmo A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Altrecht Institute for Mental Health Care   (Netherlands)

^c Ziekenhuis Walcheren   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LITHIUM CHLORIDE; MONOKINE; MOOD STABILIZER; PSYCHOTROPIC AGENT; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1; NEUROLEPTIC AGENT;

ADULT; AGE; BIPOLAR DISORDER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED DISEASE; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOGENESIS; IN VITRO STUDY; KERATINOCYTE; LETTER; MALE; MONOCYTE; PRIORITY JOURNAL; PSORIASIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LITHIUM CHLORIDE; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044506532     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2005.00214.x     Document Type: Letter

References (9)

1. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59-75.
2. Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000; 33: 159-164.
3. Chan HH, Wing Y, Su R, Van Krevel C, Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000; 57: 107-113.
4. Prinz JC. Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332.
5. Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 2002; 27: 578-584.
6. Kapp A. The role of cytokines in the psoriatic inflammation. J Dermatol Sci 1993; 5: 133-142.
7. van Haarst JM, Verhoeven GT, de Wit HJ, Hoogsteden HC, Debets R, Drexhage HA. CD1a+ and CD1a- accessory cells from human bronchoalveolar lavage differ in allostimulatory potential and cytokine production. Am J Respir Cell Mol Biol 1996; 15: 752-759.
8. Debets R, Hegmans JP, Croughs P et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997; 158: 2955-2963.
9. 3) on in-vitro-cultured normal human skin explants. J Eur Acad Dermatol Venereol 2000; 14: 97-99.